NCT03583554View on ClinicalTrials.gov

Electrophysiological Biomarkers of AV-101

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

October 19, 2019

Study Completion Date

October 19, 2019

Conditions
Healthy
Interventions
DRUG

Placebo

Single dose of 4 placebo oral capsules

DRUG

AV-101 720 mg

Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules

DRUG

AV-101 1440 mg

Single dose of 4 360 mg AV-101 oral capsules

Trial Locations (1)

77030

Michael E. DeBakey VA Medical Center, Houston

All Listed Sponsors
collaborator

Michael E. DeBakey VA Medical Center

FED

collaborator

VistaGen Therapeutics, Inc.

INDUSTRY

lead

Marijn Lijffijt, PhD

OTHER

NCT03583554 - Electrophysiological Biomarkers of AV-101 | Biotech Hunter | Biotech Hunter